Rapidly cooling a person in cardiac arrest may improve their chance of survival without brain damage, according to research presented at the American Heart Association’s Scientific Sessions 2009.
“We now have a method that is safe and can be started within minutes of cardiac arrest to minimize damage during this very critical period,” said Maaret Castrén, M.D., lead author of the study and professor of emergency medicine at the Karolinska Institute in Stockholm.
For years, people hospitalized after cardiac arrest have been cooled to reduce injury to the brain and other tissues that occurs when the blood supply returns after being temporarily halted.
In the PRINCE (Pre-Resuscitation Intra-Nasal Cooling Effectiveness) investigation, Castrén and colleagues at 14 other centers across Europe used a new tool, RhinoChill, that cools the brain during ongoing cardiopulmonary resuscitation (CPR).
Researchers randomized 200 adults going into witnessed cardiac arrest to receive either standard resuscitation or resuscitation with cooling started as soon as possible during the arrest, with ongoing CPR. All patients who survived to hospitalization were further cooled according to standard criteria. Eighteen patients were excluded from the analysis because a ‘do-not-resuscitate’ order was found or there was a non-cardiac reason for their cardiac arrest.
In the 182 patients reported, 83 (average age 66 years, 71 percent male) were randomized to receive nasal cooling (although two were not cooled because of user or device problems) and 99 (average age 64.8, 78 percent male) received standard care.
RhinoChill is a non-invasive device that introduces coolant through nasal prongs. The system is battery-powered and requires no refrigeration, making it suitable for emergency medical technicians in the field to use while a person is receiving CPR.
The patients in each group were similar in their initial heart rhythms, how much time lapsed before CPR was started and whether CPR restored a pulse. The median time between arrest and the initiation of cooling was 23 minutes. On arrival at the hospital, the cooled patients’ temperatures (measured at the eardrum) were significantly lower (average 34.2ºC, 93.56ºF) than those receiving standard care (35.5ºC, 95.9ºF, p = 0.0001).
In the total group:
- 46.7 percent of those cooled survived to hospital discharge, compared with 31 percent of those receiving standard care;
- 36.7 percent of those cooled were in good neurological condition on hospital discharge, compared with 21.4 percent of those receiving standard care.
In the 137 patients in whom resuscitation efforts began within 10 minutes of cardiac arrest:
- 59.1 percent of those cooled survived to hospital discharge, compared with 29.4 percent of those receiving standard care;
- 45.5 percent of those cooled were neurologically intact at hospital discharge, compared with 17.6 percent of those receiving standard care (p=.01).
“Our results show that the earlier you can do the cooling, the better,” Castrén said. “When resuscitation efforts were delayed, there was no significant difference in survival.”
In a time analysis, patients who received a combination of early CPR started within six minutes of collapse and cooling had the best outcomes.
Patients with ventricular fibrillation (VF), whose heart chambers aren’t pumping blood because they are twitching rapidly and erratically instead of fully contracting, are the subgroup of cardiac arrest patients most likely to survive. In this study, of the 56 patients who had VF:
- 62.5 percent of those cooled survived to hospital discharge, compared with 47.6 percent of those who received standard care;
- 50 percent of those cooled were neurologically intact at hospital discharge, compared to 28.6 percent of those who received standard care.
“RhinoChill is easy and safe to use during a cardiac arrest outside of the hospital,” said Denise Barbut, M.D., senior author of the study and president and chairman of BeneChill, Inc., maker of the device. “Although the study was not powered to look at outcomes, there seemed to be a significant benefit on survival and neurologically intact survival, specifically in those treated within 10 minutes.”
Eighteen adverse reactions were reported after the treatment, including three nosebleeds and 13 nasal discolorations. Coloring spontaneously returned to normal in all patients who survived. Serious adverse events, such as seizure or repeat cardiac arrest, occurred in seven cooled patients and 14 controls.
RhinoChill has been approved for marketing in Europe and the company expects to start selling the device there in March 2010.
Other authors are Per Nordberg, M.D.; Didier Desruelles, M.D.; Frank Eichwede, M.D.; Pierre Mols, M.D., Ph.D.; Leif Svensson, M.D., Ph.D.; Fabio Taccone, M.D.; Jean-Louis Vincent, M.D., Ph.D.; Hans-Jörg Busch, M.D.; Michael Vergnion, M.D.; Christian Storm, M.D.; Antonio Pesenti, M.D., Ph.D.; Fabien Guérisse, M.D.; Thomas Elste, M.D.; Markus Roessler, D.E.A.A.; Harald Fritz, M.D.; and Pieterjan Durnez, M.D.
Author disclosures are on the abstract.
Funding: BeneChill, Inc.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.
Note: Actual presentation time is 6:15 p.m., Sunday, Nov. 15, 2009